Digilab BioVisioN receives ISO 9001:2000 Certificate

08-Aug-2007 - Digilab BioVisioN GmbH announced it has received ISO 9001:2000 certification by the TÜV Rheinland. The certification comprises Digilab BioVisioN's business of offering research collaborations and services. These collaborations and services encompass discovery of peptide biomarkers and the ...

Digilab Peptidomics receives United States Patent for Alzheimer's Disease Biomarkers

12-Jul-2007 - Digilab Peptidomics®, formerly BioVisioN, was granted a patent by the US Patent Office for a new panel of biomarkers for the diagnosis of chronic dementia or a predisposition to such diseases. Using proprietary Peptidomics®-Technologies, scientists from Digilab Inc have discovered a group of ...

Digilab BioVisioN GmbH closes cooperation agreement with Boehringer Ingelheim

06-Apr-2006 - Digilab BioVisioN GmbH announced closing of a cooperation contract with Boehringer Ingelheim Pharma GmbH & Co. KG. This is the first collaboration contract of the company that takes over commercial activities from BioVisioN AG within a reorganization process. Within the project Digilab BioVisioN ...

BioVisioN receives research grant within BioChancePLUS program

08-Aug-2005 - BioVisioN AG announced the receipt of approval of a research grant within the German BioChancePLUS program. The German Federal Ministry of Education and Research (BMBF) will fund the Project on "Functional Peptidomics" that aims at the characterisation of proteases and protease inhibitors with ...

BioVisioN AG sells its subsidiary ImVisioN GmbH to Nextech Venture, L.P.

10-May-2005 - German biotech company BioVisioN AG has sold its spin-off, ImVisioN GmbH, to the Swiss based life science investment firm Nextech Venture, L.P. ImVisioN focuses on the development of novel immunotherapeutics based on its proprietary MAT (Modular-Antigen-Transport) technology to treat allergic ...

BioVisioN AG receives United States Patent for Peptide-Biomarker Discovery and Identification Technology

12-Apr-2005 - The patent office of the United States of America has granted the patent for BioVisioN's core technology, the "Differential Peptide Display"® (DPD), for the discovery and identification of peptide biomarkers. The methods allow the analysis and comparison of peptides in any biological sample and ...

ImVisioN GmbH - BioVisioN spins off new enterprise with peptide vaccine portfolio

13-Dec-2004 - BioVisioN announces the spin-off of a drug portfolio for causative treatment of allergic diseases - This drug portfolio may lead the way to a new concept for vaccination applicable also to other indications. Today the CEO of the Hannover, Germany based company BioVisioN AG, Dr. Sven Rohmann, ...

Cooperation between BioVisioN and Roche Diagnostics

Roche Diagnostics is validating new marker candidates for diagnosis of Alzheimer Disease

28-May-2003 - Since entering into a cooperation project with Roche Diagnostics GmbH of Mannheim in 1999, Hanover-based biotechnology firm BioVisioN has identified a number of proteins that may enable early diagnosis of Alzheimer's Disease and distinguish it from other forms of dementia. The cooperation between ...